Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
about
Brodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesThe Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTHWhat makes psoriatic and rheumatoid arthritis so different?Inflammation, immunity, and hypertensive end-organ damagePouring fuel on the fire: Th17 cells, the environment, and autoimmunityInterleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseasesT Helper Cell Subsets in Clinical Manifestations of PsoriasisEffect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesEmerging Therapies for Rheumatoid ArthritisIntracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathwayEfficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)T cell activation and differentiation is modulated by a CD6 domain 1 antibody ItolizumabCytokine-modulating strategies and newer cytokine targets for arthritis therapy.Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perioComparative genomic profiling of synovium versus skin lesions in psoriatic arthritis.Bone-immune cell crosstalk: bone diseases.Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment.The Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesIL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in MicePain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study.Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18.The pathogenic role of angiogenesis in rheumatoid arthritis.Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritisAdvances in the management of psoriatic arthritis.Proteomics focusing on immune markers in psoriatic arthritis.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.New treatments for inflammatory rheumatic disease.Emerging drugs for the treatment of axial and peripheral spondyloarthritis.Efficacy and safety of emerging immunotherapies in psoriasis.Ixekizumab for treatment of psoriasis.The IL-23-IL-17 axis in inflammatory arthritis.Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis.Pharmacological therapy of spondyloarthritis.Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.Psoriatic arthritis: latest treatments and their place in therapy.
P2860
Q26746100-48B685CA-1015-42EC-B6A3-B41869125491Q26764867-7F6B7316-2F32-4BC3-90B5-9E1A6344B710Q26765844-2C165CDF-0F69-435C-8297-8A180ABD3B39Q26778261-728CAA74-A233-4C9B-8160-1DA55BD7D02BQ26827525-64EBCBF6-F3CD-4E01-BAC4-0D3DA4A706CCQ26863295-AAC0F5ED-2C18-4833-BFE9-B382A9ECECB4Q28069350-0E820A8C-D03E-4BFC-AEC9-50016C952747Q28069848-D9947F31-FD09-42B1-9BE2-5A41AB94937EQ28076496-65FDD68E-DA56-41FC-AAE9-C47F7116B0E1Q28078943-4208E743-F7EE-4B6E-8A9A-C581461DF29DQ30724821-0CDC6EFF-1888-488D-9D11-3780625039EDQ33626095-79B5517E-5485-4D50-A1EB-924E701E8BFBQ33865748-6AFA67F8-EA3D-4A05-867D-56508C3BC7A9Q34456715-F5C90CA0-7ADD-434F-B6CF-34FD33607655Q34538249-89BA9955-A5AC-4FC5-9CF8-F304FC2DDC44Q35522947-E651F495-2F8F-4958-B523-4E13E14C6970Q35592362-8785067A-2751-428D-A02A-27AA92BDB99EQ36167063-1C2ADDAB-D628-4EDD-AE68-B06E6C7193E0Q36249305-9CA51969-BB49-4A45-84D9-7A462F7C06DAQ36253707-494C467E-FF2C-4598-B066-1460C5C057C7Q36819032-641C5797-378A-414F-BECE-4F0D05B460C5Q36905009-4FB1B773-4425-4C63-9CAC-EF56329C7876Q36934777-DD87196A-993D-4AB0-81DF-329F023225DCQ36968787-19BA527D-C78A-43FA-BE79-8F74CBA49736Q37460263-F199C1B9-4B08-4371-9916-68CB641F3D68Q38227264-FEBB37C6-F06E-4AFC-923F-D30D03691D36Q38230695-2A27B932-DA13-46AF-8C2A-E08AC48532DBQ38255855-5999544B-E84F-467E-8624-8FDC753E36DBQ38264660-FF9EAC6D-8F0B-4175-990F-950081F620F4Q38266252-391D6EDF-0CA7-4B3A-9FCD-FC6458183C16Q38313266-90F0FD4C-5787-40B3-940D-219EAEBB3237Q38365042-C0A9792D-67DD-40AE-BF84-22581D4D5E80Q38369782-4BCC8128-11CC-449F-95B5-905E93AD5022Q38439641-3ECF08AE-3BDD-46EC-8EE5-736F5D47D3EBQ38445314-B94BF3EC-2674-46C9-974C-81417AECAB8DQ38458004-889B8A2A-AAA4-4E44-ABB4-F96FB9CCC55FQ38488577-1CAE1C63-C28D-49B9-8ADB-0C766DEDF1ABQ38527552-B09E6668-D474-43A3-88CF-CDFF30A99D57Q38539811-A01A18AF-CA57-4DA4-8322-3E99AB06E8BEQ38542095-38470930-8BE0-43ED-B7AA-A29AD97E64BE
P2860
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@en
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@nl
type
label
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@en
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@nl
prefLabel
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@en
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@nl
P2093
P356
P1476
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
@en
P2093
Ajay Nirula
André D Beaulieu
Atul Deodhar
JingYuan Feng
Maria W Greenwald
Mark C Genovese
Ngozi Erondu
Philip J Mease
Richard Newmark
P304
P356
10.1056/NEJMOA1315231
P407
P577
2014-06-01T00:00:00Z